

21st March, 2026

To,

**The Corporate Relationship Department
BSE Limited**

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001.

Scrip Code: 539523

National Stock Exchange of India Limited
Exchange Plaza,

Bandra Kurla Complex,
Bandra East,
Mumbai 400 051.

Scrip Symbol: ALKEM

Sub: Press Release – Alkem Laboratories launches Semaglutide injection in India, with weekly therapy starting at INR 450/-

Dear Sir(s)/ Madam,

This is to inform you that Alkem Laboratories Limited (the “Company”), one of the leading pharmaceutical companies, today announced the launch of Semaglutide injection in India for type-2 diabetes mellitus and chronic weight management, thereby improving accessibility and enabling better healthcare outcome for patients.

A press release in this regard is enclosed herewith.

Request you to kindly take the same on record.

Sincerely,

For **Alkem Laboratories Limited**

Manish Narang

President – Legal, Company Secretary & Compliance Officer

Alkem Laboratories launches semaglutide injection in India at weekly therapy cost starting INR 450

- *Alkem's semaglutide is available in a pre-filled disposable injection pen, containing four doses for a month, at an affordable price starting INR 1,800*
- *Alkem is also offering reusable injection pen for higher maintenance doses*

Mumbai, March 21, 2026: Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM, "Alkem" and its subsidiaries) today announced the launch of semaglutide injection in India under the brand names "*Semasize*", "*Obesema*" and "*Hepaglide*". Semaglutide is administered as a subcutaneous injection, once weekly.

The company has launched its semaglutide pre-filled disposable injection pen at a price starting INR 1,800 for a month's dosage, which translates into a weekly cost of INR 450. Through an affordable pricing, Alkem aims to lower barriers to initiation and expand access to this therapy in India.

Alkem has received approval from the Drug Controller General of India (DCGI) for manufacturing and marketing semaglutide for type 2 diabetes mellitus and chronic weight management as an adjunct to diet and exercise, subsequent to a review of its Phase 3 clinical trials conducted in India. Semaglutide is a prescription product and should be taken under appropriate medical supervision.

Apart from disposable pen, Alkem is offering reusable injection pen for semaglutide administration for higher maintenance doses. The reusable pen enables patients to replace only the medication cartridge rather than purchasing a new disposable pen each time, thereby reducing cost and helping better patient adherence to treatment.

Commenting on the launch, Dr. Vikas Gupta, Chief Executive Officer, Alkem said, "We believe therapeutic advancements must translate into real-world access to create a lasting impact. With the launch of our indigenously-developed semaglutide, we are bringing a high-quality and affordable option to market, empowering healthcare practitioners to offer this therapy to more deserving patients. Through our strong distribution network and patient-friendly devices, we aim to make the product accessible to a larger section of the population and contribute to better overall healthcare outcomes."

--End--

About Alkem:

Alkem Laboratories Ltd. is a leading Indian pharmaceutical company with a legacy of over 50 years in providing high quality medicines to patients. It is the sixth largest pharmaceutical company in the Indian market with a dominant position in the therapy areas of anti-infectives, gastrointestinal, pain management drugs and supplements. It also has a growing portfolio of products in chronic therapies such as diabetes, neurology, cardiology, dermatology and urology. It has 18 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centres across India and the US to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has meaningful presence in the US, Latin America, Australia and several Asian countries. “Inspiring Healthier Lives” is at the core of the values and culture of the organisation and reinforces its steadfast commitment to global health improvement. For more information, please visit www.alkemlabs.com and follow us on [LinkedIn](#), [Instagram](#), [Facebook](#).

Contacts

Media: Isha Trivedi alkemcorpcomm@alkem.com +91-98925 90003	Investors: Purvi Shah purvi.shah@alkem.com +91-84337 00890
--	--